Could these micro-caps provide an upward return of 500%?

The stock market is uncertain but what is certain is that no one can accurately predict the expiration date of the coronavirus. The current volatility is turning the market into a casino. However, many investors are turning the odds in their favour by creating coronavirus strategies. Do you want to turn the odds in your […]

Why did Ex-NFL player Mitch Marrow call PAR’s drug life changing?

A silver lining in the current bearish decline is the opportunity to possibly enter strong stocks like Paradigm Biopharmaceuticals (ASX: PAR). PAR is one of Australia’s most talked-about biotechs of 2019 and 2020 so far. PAR strives to alleviate the suffering and cartilage degradation of Osteoarthritis patients through its repurposed drug Zilosul. Today we will […]

Here’s why PAR is worth watching now more than ever?

When thinking of a biotech market mover Paradigm Biopharmaceuticals (ASX: PAR) instantly comes to mind. Paradigm, through its repurposed drug Zilosul, aims to alleviate the suffering and cartilage degradation of Osteoarthritis. PAR’s impressive clinical developments in osteoarthritis and 240% surge in 2019 captivated both the scientific and investment world. Paradigm kickstarted 2020 off with a […]

Will PAR’s H1 2020 financials trigger a surge this week?

In my opinion, biotechnology is the most entertaining industry in the stock market. Why? Three reasons.   1) Biotech tends to be up even when the market is down. Because our ageing population continues to demand the best medicine to sustain a higher life expectancy. 2) Second, there is a range of top-quality biotechs under […]

Has the coronavirus created a possible entry for PAR ?

Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. If you have not heard of Paradigm BioPharmaceuticals (ASX: PAR) then today is your lucky day. PAR is an Australian BioPharmaceutical company that aims to alleviate the cartilage degradation of […]

Update: Will Paradigm’s stock price surge continue into 2020?

Why all the excitement in 2019? Paradigm Biopharmaceuticals captivated investors with an impressive 300% rise over 2019. Paradigm aims to alleviate the suffering and cartilage degradation of Osteoarthritis through their repurposed drug Zilosul. PAR’s rapid stock rise was due to the company’s outstanding collection of clinical data on Zilosul. For any Biotech to achieve success, […]

Paradigm Bio-Pharmaceutical (ASX) with major stock movement- how long will it hold ?

Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Since launching , YIG has published articles relating to commodities (Cobalt) and Tech companies. Now, YIG has a new and exciting list of companies that will be assessed, to give […]